Clinical Trials · NCT07417631

Emulation of the REWIND Cardiovascular Outcomes Trial in Healthcare Claims Data.

Phase
N/A
Recruitment status
Completed
Sponsor
Brigham and Women's Hospital
Enrollment
300,000
Start date
Feb 2026
Locations
1 site, United States
Primary endpoint
Time to first occurrence of myocardial infarction, stroke, or all-cause mortality
View Dulaglutide compound reference